Laddar...
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
Immune checkpoint therapy has resulted in remarkable improvements in the outcome for certain cancers. To broaden the clinical impact of checkpoint targeting, we devised a strategy that couples targeting of the cytokine-inducible Src homology 2–containing (CIS) protein, a key negative regulator of in...
Sparad:
| I publikationen: | Blood |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
American Society of Hematology
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7869185/ https://ncbi.nlm.nih.gov/pubmed/32902645 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007748 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|